ABT vs STOK · P/E 25, rev $44.33B vs rev $15.6M
Abbott Laboratories (ABT) versus Stoke Therapeutics Inc (STOK) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Stoke Therapeutics Inc (STOK) is a biotechnology company listed on NASDAQ.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported STOK revenue for 2026-06-30 was $15.6M. Net income was -$111.6M. STOK currently screens at market cap $1.88B.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. STOK currently screens at market cap $1.88B.
Not investment advice. Open the ABT and STOK stock pages for the full models.
Not investment advice.